Our research revealed that by inhibiting the expression of KLF4, the promotion of pro-tumoral macrophage polarization and the malignant biological behavior of NSCLC induced by ADRB2 agonists could be nullified. The gene discussed is ADRB2; the disease is non-small cell lung carcinoma.